Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment

Katharina S Shaw; Diana B Reusch; Rochelle L Castillo; Kimberly B Hashemi; Robert Sundel; Fatma Dedeoglu; Ruth Ann Vleugels

doi:10.1001/jamadermatol.2023.4744

Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment

JAMA Dermatol. 2024 Feb 1;160(2):237-238. doi: 10.1001/jamadermatol.2023.4744.

Authors

Katharina S Shaw¹, Diana B Reusch², Rochelle L Castillo^{2

3}, Kimberly B Hashemi^{2

3}, Robert Sundel⁴, Fatma Dedeoglu⁴, Ruth Ann Vleugels^{2

3}

Affiliations

¹ Section of Dermatology, Department of Dermatology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Dermatology Program, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.
⁴ Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts.

PMID: 37950917
DOI: 10.1001/jamadermatol.2023.4744

No abstract available

Plain language summary

This case report describes a 14-year-old girl with juvenile dermatomyositis who presented with a 6-year history of a pruritic, photosensitive eruption involving her face, neck, trunk, and extremities and was successfully treated with anifrolumab.

MeSH terms

Administration, Cutaneous
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatomyositis* / drug therapy
Humans
Skin

Substances

anifrolumab
Antibodies, Monoclonal, Humanized